{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-25-000004","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.502783+00:00","generated_at":"2026-05-24T09:52:46.781729+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SELLAS reports FY2024 net loss $30.9M; Phase 3 REGAL trial interim analysis positive","bullets":["Net loss $30.9M ($0.50/share) vs $37.3M ($1.34) in FY2023; R&D expenses down to $19.1M.","Cash $13.9M at Dec 31, 2024; raised $25M in January 2025 registered direct offering.","Positive interim analysis for Phase 3 REGAL trial (GPS in AML); final analysis expected upon 80 events in 2025.","Phase 2 SLS009 in r/r AML: 56% ORR in AML-MRC cohorts; median OS >7.7 months vs historic ~2.5 months.","Received multiple regulatory designations: three FDA RPDD, one Fast Track, two EMA ODD."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-25-000004","json":"https://secwatch.observer/filing/0001390478-25-000004.json","markdown":"https://secwatch.observer/filing/0001390478-25-000004.md","text":"https://secwatch.observer/filing/0001390478-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/0001390478-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/sls-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T09:52:46.781729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}